1. Aged 18-75, male and female, with ECOG score of 0 or 1;
2. Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
3. underwent PD-L1 IHC examination before therapy;
4. The expected survival was more than 26 weeks;
5. Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \>= 4.0 x 10\^9/L or neutrophil \>= 1.5 x 10\^9/:, PLT \>= 100 x 10\^9 / L, Hb \>= 90g / L; Pt or APTT \<= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \<= 1.5 x ULT (upper limit of normal value), ALT / AST \<= 2.5 upper limit of normal value or \<= 5 x ULT (subject with liver metastasis), ALP \<= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \<= 4.5 upper limit of normal value); BUN \<= 1.5 x ULT, SCR \<= 1.5 x ULT;
6. According to RECIST1.1, there was at least one measurable target lesion;
7. Understand and sign informed consent voluntarily with good compliance.
You may not be if
1. The function of liver and kidney was seriously abnormal;
2. Preparation for pregnant, pregnant and lactating women;
3. Inability to lie flat for half an hour;
4. Suffering from claustrophobia or other mental disorders;
5. Other researchers considered it unsuitable to participate in the trial.
Clareo Health | PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
